Novum Pharmaceutical Research Services Announces New Medical Director of Dermatology

Novum Pharmaceutical Research Services has announced that Orin Goldblum, MD has joined its executive team as Medical Director of Dermatology and Locally Acting Products.

Pittsburgh, PA (PRWEB) January 08, 2013

Novum Pharmaceutical Research Services has announced that Orin Goldblum, MD has joined its executive team as Medical Director of Dermatology and Locally Acting Products.

Dr. Goldblum, a Board Certified Dermatologist, has 27 years of experience as both a practicing physician and in dermatology clinical research. His areas of expertise include clinical trial design, and Phase I – Phase IV drug development studies. Dr. Goldblum is a graduate of the University of Pittsburgh School of Medicine, and completed his postgraduate training in the Department of Dermatology at the Johns Hopkins Medical Institutions.

Dr. Goldblum will replace Dr. Darin Brimhall, who assumed the role of Novum's Vice President of Phase I Clinical Operations on January 1, 2013.

Chris Chamberlain, Novum's CEO, said, “With his extensive clinical trial and medical experience, Dr. Goldblum will further strengthen Novum's leadership in clinical research in the field of dermatology. We are extremely pleased to welcome him to our team.”

Before joining Novum, Dr. Goldblum served as Medical Director, Immunology Medical Affairs in Global Pharmaceutical Research and Development with Abbott Laboratories. He served as the lead physician on a global postmarketing registry for a biologic used in treating psoriasis.

Prior to joining the pharmaceutical industry, Dr. Goldblum led a private medical and surgical dermatology practice for over 20 years, where he actively participated as an investigator in clinical research studies. He holds two patents in the dermatology field. Dr. Goldblum has also served as a Clinical Instructor and Clinical Assistant Professor of Dermatology at the University of Pittsburgh School of Medicine.

Gail Gongas, VP of clinical trials for Novum, said, “Novum has completed 45 later stage dermatology studies enrolling over 20,000 patients. Having Dr. Goldblum join us as Medical Director will not only increase our expertise base, but allow Novum to provide our clients significantly expanded service offerings across all clinical phases of dermatology research.”

Dr. Goldblum has published extensively and holds professional memberships with the American Academy of Dermatology and the European Academy of Dermatology and Venereology.

About Novum PRS
Novum is a contract research organization ("CRO") that provides Phase I through IV clinical research, data management, statistical and reporting services to the pharmaceutical and related industries. Founded in 1972, it operates Phase I research facilities with a total of 550 beds in three USA locations. Novum's expanding clinical trials management group currently focuses on performing Phase II through IV clinical endpoint studies requiring large patient numbers in ambulatory disease populations. Visit http://www.novumprs.com for more information.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10299937.htm